Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($0.99), $0.58 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $10 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.